Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells

Area of Science:

• Neuroscience
• Pharmacology
• Cell Biology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by memory loss and cognitive decline.
• Key pathological hallmarks of AD include Tau protein aggregation and hyperphosphorylation, leading to neuronal dysfunction.
• Identifying natural compounds with neuroprotective properties is crucial for developing novel AD therapeutics.

Purpose of the Study:

• To investigate the efficacy of ethanolic Bacopa monnieri extract in inhibiting Tau aggregation.
• To evaluate the neuroprotective effects of Bacopa monnieri in Tau-stressed neuronal cells.
• To elucidate the underlying mechanisms of Bacopa monnieri's action, including its antioxidant and anti-inflammatory properties.

Main Methods:

• In vitro assessment of Bacopa monnieri's effect on Tau aggregation.
• Cell viability assays on Tau-stressed Neuro2a cells treated with Bacopa monnieri.
• Analysis of reactive oxygen species (ROS) levels, caspase-3 activity, and Nrf2 pathway activation.
• Immunoblot and immunofluorescence techniques to assess phospho-Tau levels, GSK-3β phosphorylation, and NUP358 localization.

Main Results:

• Bacopa monnieri extract significantly inhibited Tau aggregation in vitro.
• Treatment with Bacopa monnieri reduced ROS levels and caspase-3 activity in Tau-stressed cells.
• The extract demonstrated antioxidant effects by restoring Nrf2 levels and reducing phospho-Tau load.
• Bacopa monnieri mitigated formaldehyde-induced impairment of nuclear transport by correcting NUP358 arrangement.

Conclusions:

• Bacopa monnieri exhibits potent inhibitory effects against Tau phosphorylation and aggregation.
• The herb demonstrates neuroprotective properties through antioxidant mechanisms and restoration of cellular transport.
• These findings suggest Bacopa monnieri as a promising natural agent for Alzheimer's disease management.